Aptamer Synthesis Service
Nucleic acid aptamers, also known as "aptamers," can be understood as "antibodies" composed of nucleic acids. They are a novel class of recognition molecules that fold into specific three-dimensional structures, allowing them to bind to biological targets with high affinity and specificity. Aptamers are single-stranded DNA or RNA molecules that possess several advantages such as small molecular weight, chemical synthesis capability, good stability, lack of immunogenicity and toxicity, and broad target specificity. These characteristics provide aptamers with unparalleled advantages over traditional immunological and chemical recognition methods. In recent years, the FDA has approved an increasing number of aptamer drugs and small nucleic acid drugs, indicating a positive trend. As a result, both basic research and applied research in this field have shown rapid development.
The selection of nucleic acid aptamers typically involves the binding of oligonucleotide libraries to target substances, followed by several rounds of screening and amplification in vitro to determine their functionality. This process is commonly referred to as Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technology. Through SELEX, aptamers ranging from 20 to 100 nucleotides in length with good affinity and specificity for the target ligand can be selected from the oligonucleotide library. These aptamers can then be used as drug carriers for downstream nucleic acid drug development.
We have extensive experience in small nucleic acid synthesis, library synthesis, and screening. We offer services for protein target-based nucleic acid aptamer screening and synthesis, ultimately delivering at least one nucleic acid aptamer sequence with a KD<300nM.
SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory